Your session is about to expire
← Back to Search
Procedure
Single vs Multiple Arterial Grafts for Heart Disease (ROMA Trial)
N/A
Waitlist Available
Led By Mario Gaudino, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Primary isolated CABG patients with disease of the left main coronary artery and/or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.
Be older than 18 years old
Must not have
Inability to use the saphenous vein or to use both radial and right internal thoracic arteries
Anticipated need for coronary thrombo-endarterectomy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up analysis will be performed after 631 events. the investigators assume this will occur at a mean follow-up of 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether using multiple arterial grafts (2+) is better than using a single arterial graft for coronary artery bypass surgery in terms of reducing the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization.
Who is the study for?
This trial is for patients with coronary artery disease who need non-emergency heart bypass surgery and haven't had previous cardiac surgeries. It's not for those over 70, with recent heart attacks, severe heart failure, or other serious health issues that could limit life expectancy to under 5 years.
What is being tested?
The ROMA trial is testing if using multiple arterial grafts in heart bypass surgery is better than a single graft at reducing death, strokes, heart attacks, and the need for more surgery. Patients are randomly assigned to either group in equal numbers across international centers.
What are the potential side effects?
While specific side effects aren't listed here, typical risks of bypass surgery may include bleeding, infection, reactions to anesthesia, blood clots leading to stroke or lung problems; irregular heartbeat; and kidney problems.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have heart disease affecting specific arteries.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I cannot use my saphenous vein or both my radial and right internal thoracic arteries.
Select...
I am expected to need surgery to remove blockages from my heart's arteries.
Select...
I am undergoing or have undergone other heart or non-heart related surgeries.
Select...
I do not have severe organ problems or other conditions that would shorten my life to under 5 years.
Select...
I am scheduled for a combined surgical and non-surgical procedure to improve blood flow.
Select...
I need an emergency surgery.
Select...
I have not had a heart attack within 2 days before surgery.
Select...
I have had heart surgery in the past.
Select...
I am over 70 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ analysis will be performed after 631 events. the investigators assume this will occur at a mean follow-up of 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~analysis will be performed after 631 events. the investigators assume this will occur at a mean follow-up of 5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Composite Outcome
Secondary study objectives
30-day mortality
Heart
Composite Outcome of Death from any cause
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Single Arterial GroupExperimental Treatment1 Intervention
Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
Group II: Multiple Arterial GroupExperimental Treatment1 Intervention
Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,083 Previous Clinical Trials
1,134,499 Total Patients Enrolled
15 Trials studying Coronary Artery Disease
44,143 Patients Enrolled for Coronary Artery Disease
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,922 Previous Clinical Trials
47,756,446 Total Patients Enrolled
166 Trials studying Coronary Artery Disease
264,904 Patients Enrolled for Coronary Artery Disease
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,386 Previous Clinical Trials
26,511,675 Total Patients Enrolled
25 Trials studying Coronary Artery Disease
25,178 Patients Enrolled for Coronary Artery Disease
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot use my saphenous vein or both my radial and right internal thoracic arteries.I am expected to need surgery to remove blockages from my heart's arteries.I am undergoing or have undergone other heart or non-heart related surgeries.I do not have severe organ problems or other conditions that would shorten my life to under 5 years.I am scheduled for a combined surgical and non-surgical procedure to improve blood flow.I need an emergency surgery.Your heart is not pumping enough blood effectively.Only one transplant allowed.I have not had a heart attack within 2 days before surgery.I have had heart surgery in the past.I am over 70 years old.I have heart disease affecting specific arteries.
Research Study Groups:
This trial has the following groups:- Group 1: Single Arterial Group
- Group 2: Multiple Arterial Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger